Santen Pharmaceutical (4536) · InitiativeFirst stated

Streamlining the business portfolio through the transfer of U.S. subsidiary AVS

First written in FY2027-H1. . Latest entry: FY2027-H1.

1entries

1years

0from disclosures

How it moved

Same theme, other companies

Removal from the Scope of Consolidation Through the Transfer of Shares in a SubsidiaryA theme 354 companies write about · 51 as a headwind · 254 as a tailwind

21 other companies' latest entry also says "First stated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.

Showing 14 of the 158 companies compared. The sentences above are computed from all 158.Comparing 200 of the theme's 450 threads.

Full recordFilings, disclosures and news, newest first

FY2027-H1First statedAnnual report
「On 1 October 2026, the Santen Group transferred all issued shares of Advanced Vision Science, Inc., its U.S. subsidiary (hereinafter “AVS”), to SpyGlass Pharma, Inc. of the United States. As a result, AVS will be excluded from the Santen Group's consolidated subsidiaries. The Company plans to record an approximately ¥800 million gain on the sale of shares in a subsidiary under “other income” in FY2027.」
The Company transferred all AVS shares to SpyGlass Pharma and excluded AVS from its consolidated subsidiaries. It discloses that, in connection with the sale, it plans to record an approximately ¥800 million gain on the sale of shares in a subsidiary in FY2027.

Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next

No upcoming earnings preview for Santen Pharmaceutical yet.

News

No news is linked to this thread yet. When an article touches it, it will appear here by date.